ConductScience.org, home

Comparison · NCT00092547-8ff70712

qHPV Vaccine in Base Study vs qHPV Vaccine in Extension Study: Number of Participants Reporting SAEs From Month 18 Through Month 37

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. qHPV Vaccine in Base Study vs qHPV Vaccine in Extension Study: Number of Participants Reporting SAEs From Month 18 Through Month 37. Trial comparisons, record NCT00092547-8ff70712. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00092547-8ff70712

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.00414wilson
Risk in group 20.006290.002140.0183wilson
Risk difference, group 1 minus group 2-0.00629-0.0183-0.000425newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one fewer participant with the outcome on qHPV Vaccine in Base Study than on qHPV Vaccine in Extension Study15954.62,350from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1qHPV Vaccine in Base StudyRepresents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 60923OG000
Group 2qHPV Vaccine in Extension StudyRepresent participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.3477OG001

Outcome

Type
PRIMARY
Title
Number of Participants Reporting SAEs From Month 18 Through Month 37
Description
Tolerability as assessed by the number of participants with clinical adverse experiences from Month 18 through Month 37
Time frame
Month 18 to Month 37
Population
All participants who were vaccinated according to actual treatment received (qHPV or placebo) and had safety follow-up.

Source ClinicalTrials.gov

Trial

Title
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
NCT number
NCT00092547
Phases
PHASE3
Conditions
Human, Papillomavirus Infections
Interventions
V501, Comparator: Placebo
Lead sponsor
Merck Sharp & Dohme LLC
Results first posted
2010-05-04

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00092547-8ff70712